Medical treatment of otosclerosis: Rationale for use of bisphosphonates

International Tinnitus Journal

Volumn 14, Issue 2, 2008, Pages 92-96

  Brookler, Kenneth H ^a  

^a Neurotologic Associates   (United States)

Author keywords

Bisphosphonates; Osteoclastogenesis; Osteoprotegerin (OPG); Otosclerosis; Receptor activator nuclear kappa ligand (RANKL)

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; FLUORIDE SODIUM; FLUOROPHOSPHATE; RISEDRONIC ACID; VITAMIN D;

ADULT; ARTICLE; BASIC RESEARCH; BONE TURNOVER; CASE REPORT; CELL DEATH; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPREHENSION; EXPERIMENTAL ANIMAL; HEARING LOSS; HISTOPATHOLOGY; HUMAN; INNER EAR; INTROSPECTION; MALE; MICROCAPSULE; OSTEOCLAST; OTOSCLEROSIS; PATHOGENESIS; PERCEPTION DEAFNESS; PRIORITY JOURNAL; STAPEDECTOMY; TEMPORAL BONE; VITAMIN SUPPLEMENTATION;

AGED; ALENDRONATE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CELL DEATH; COMBINED MODALITY THERAPY; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EAR, INNER; EAR, MIDDLE; ETIDRONIC ACID; FOLLOW-UP STUDIES; HEARING AIDS; HEARING LOSS, SENSORINEURAL; HUMANS; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOPROTEGERIN; OTOSCLEROSIS; SPEECH DISCRIMINATION TESTS; SPEECH RECEPTION THRESHOLD TEST; STAPES SURGERY; TINNITUS;

EID: 58149269234     PISSN: 09465448     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Linthicum FH Jr. Histopathology of otosclerosis. Otolaryngol Clin North Am 26:335-352, 1993.
2. Davis GL. Pathology of otosclerosis: A review. Am J Otolaryngol 8:273-281, 1987.
3. Chole RA, McKenna M. Pathophysiology of otosclerosis. Otol Neurotol 22:249-257, 2001.
4. Frisch T, Sorensen MS, Overgaard S, Bretlau P. Estimation of volume referent bone turnover in the otic capsule after sequential point labeling. Ann Otol Rhinol Laryngol 109:33-39, 2000.
5. McKenna M, Gadre AK, Rask-Andersen H. Ultrastructural characterization of otospongiotic lesions in reembedded celloidin sections. Acta Otolaryngol 109:397-405, 1990.
6. Karosi T, Jokay I, Konya J, et al. Activated osteoclasts with CD51/61 expression in otosclerosis. Laryngoscope 116:1478-1484, 2006.
7. Zehnder AF, Kristiansen AG, Adams JC, et al. Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. Laryngoscope 115:172-177, 2005.
8. Zehnder AF, Kristiansen AG, Adams JC, et al. Osteoprotegerin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss. Laryngoscope 116:201-206, 2006.
9. Menger DJ, Tange RA. The aetiology of otosclerosis: A review of the literature. Clin Otolaryngol 28:112-120, 2003.
10. Niedermeyer HP, Arnold W. Etiopathogenesis of otosclerosis. ORL J Otorhinolaryngol Relat Spec 64:114-119, 2002.
11. Niedermeyer H, Arnold W, Neubert WJ, Hofler H. Evidence of measles virus RNA in otosclerotic tissue. ORL J Otorhinolaryngol Relat Spec 56:130-132, 1994.
12. McKenna MJ, Kristiansen AG. Molecular biology of otosclerosis. Adv Otorhinolaryngol 65:68-74, 2007.
13. Karosi T, Jokay I, Konya J, et al. Expression of measles virus receptors in otosclerotic, non-otosclerotic and in normal stapes footplates. Eur Arch Otorhinolaryngol 264: 607-613, 2007.
14. Aminpour STS, Brodie HA. Role of tumor necrosis factor-alpha in sensorineural hearing loss after bacterial meningitis. Otol Neurotol 26:602-609, 2005.
15. Karosi T, Jokay I, Konya J, et al. Detection of osteoprotegerin and TNF-alpha mRNA in ankylotic stapes footplates in connection with measles virus positivity. Laryngoscope 116:1427-1433, 2006.
16. Stutzmann JJ, Petrovic AG. Diphosphonates for otospongiosis. Am J Otol 6:89-95, 1985.
17. Kennedy DW, Hoffer ME, Holliday M. The effects of etidronate disodium on progressive hearing loss from otosclerosis. Otolaryngol Head Neck Surg 109:461-467, 1993.
18. Brookler KH, Tanyeri H. Etidronate for the neurotologic symptoms of otosclerosis: Preliminary study. Ear Nose Throat J 76:371-376,379-381, 1997.
19. Chapurlat RD, Delmas PD. Risedronate: Clinical usage. Int J Clin Pract 55:275-278, 2001.
20. Crandall C. Risedronate: A clinical review. Arch Intern Med 161:353-360, 2001.
21. Shambaugh GE Jr. Fluoride therapy for otosclerosis. Arch Otolaryngol Head Neck Surg 116:1217, 1990.
22. Shambaugh GE Jr. How and when to prescribe sodium fluoride. Am J Otol 10:146-147, 1989.
23. Bretlau P, Salomon G, Johnsen NJ. Otospongiosis and sodium fluoride. A clinical double-blind, placebo-controlled study on sodium fluoride treatment in otospongiosis. Am J Otol 10:20-22, 1989.
24. Forquer BD, Linthicum FH, Bennett C. Sodium fluoride: Effectiveness of treatment for cochlear otosclerosis. Am J Otol 7:121-125, 1986.
25. Causse JR, Causse JB. Clinical studies on fluoride in otospongiosis. Am J Otol 6:51-55, 1985.
26. Adachi O, Stankovic KM, Kristiansen AG, et al. Bisphosphonates inhibit bone remodeling in the otic capsule of osteoprotegerin deficient mouse, an animal model of otosclerosis. Poster presentation, Association for Research in Otolaryngology, Phoenix, AZ, 2008.